Early Activation of Phosphatidylinositol 3-Kinase After Ischemic Stroke Reduces Infarct Volume and Improves Long-Term Behavior

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2016 Sep 4

PMID 27590139

Citations 9

Authors

Young Seo Kim

Arum Yoo

Jeong Woo Son

Hyun Young Kim

Young-Jun Lee

Sejin Hwang

Kyu-Yong Lee

Young Joo Lee

Cenk Ayata

Hyung-Hwan Kim

Seong-Ho Koh

Affiliations

Soon will be listed here.

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) have recently been implicated in apoptosis and ischemic cell death. We tested the efficacy of early intervention with a peptide PI3K activator in focal cerebral ischemia. After determining the most effective dose (24 μg/kg) and time window (2 h after MCAO) of treatment, a total of 48 rats were subjected to middle cerebral artery occlusion (MCAO). Diffusion weighted MRI (DWI) was performed 1 h after MCAO and rats with lesion sizes within a predetermined range were randomized to either PI3K activator or vehicle treatment arms. Fluid attenuated inversion recovery (FLAIR) MRI, neurological function, western blots, and immunohistochemistry were blindly assessed. Initial DWI lesion volumes were nearly identical between two groups prior to treatment. However, FLAIR showed significantly smaller infarct volumes in the PI3K activator group compared with vehicle (146 ± 81 mm and 211 ± 96 mm, p = 0.045) at 48 h. The PI3K activator group also had better neurological function for up to 2 weeks. In addition, PI3K activator decreased the number of TUNEL-positive cells in the peri-infarct region compared with the control group. Western blot and immunohistochemistry showed increased expression of phosphorylated Akt (Ser473) and GSK-3β (Ser9) and decreased expression of cleaved caspase-9 and caspase-3. Our results suggest a neuroprotective role of early activation of PI3K in ischemic stroke. The use of DWI in the randomization of experimental groups may reduce bias.

Citing Articles

Human neural stem cell-derived extracellular vesicles protect against ischemic stroke by activating the PI3K/AKT/mTOR pathway.

Wang J, Zhao M, Fu D, Wang M, Han C, Lv Z Neural Regen Res. 2024; 20(11):3245-3258.

PMID: 39248158 PMC: 11881723. DOI: 10.4103/NRR.NRR-D-23-01144.

Pharmacological inhibition of mTORC1 reduces neural death and damage volume after MCAO by modulating microglial reactivity.

Villa-Gonzalez M, Rubio M, Martin-Lopez G, Mallavibarrena P, Valles-Saiz L, Vivien D Biol Direct. 2024; 19(1):26.

PMID: 38582839 PMC: 10999095. DOI: 10.1186/s13062-024-00470-5.

GLP-1R Agonist Exendin-4 Protects Against Hemorrhagic Transformation Induced by rtPA After Ischemic Stroke via the Wnt/β-Catenin Signaling Pathway.

Liu C, Sun S, Xie J, Li H, Li T, Wu Q Mol Neurobiol. 2022; 59(6):3649-3664.

PMID: 35359227 PMC: 9148281. DOI: 10.1007/s12035-022-02811-9.

Neuroprotective Effects of GV1001 in Animal Stroke Model and Neural Cells Subject to Oxygen-Glucose Deprivation/Reperfusion Injury.

Kwon H, Kim Y, Park H, Son J, Choi H, Lee Y J Stroke. 2021; 23(3):420-436.

PMID: 34649386 PMC: 8521247. DOI: 10.5853/jos.2021.00626.

DNA methylation analyses identify an intronic ZDHHC6 locus associated with time to recurrent stroke in the Vitamin Intervention for Stroke Prevention (VISP) clinical trial.

Davis Armstrong N, Chen W, Hsu F, Brewer M, Cullell N, Fernandez-Cadenas I PLoS One. 2021; 16(7):e0254562.

PMID: 34252155 PMC: 8274879. DOI: 10.1371/journal.pone.0254562.

References

Shehadah A, Chen J, Zacharek A, Cui Y, Ion M, Roberts C . Niaspan treatment induces neuroprotection after stroke. Neurobiol Dis. 2010; 40(1):277-83. PMC: 2926170. DOI: 10.1016/j.nbd.2010.05.034. View

Savitz S . A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007; 205(1):20-5. DOI: 10.1016/j.expneurol.2007.03.003. View

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B . The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010; 11(5):329-41. DOI: 10.1038/nrm2882. View

Le D, Wu Y, Huang Z, Matsushita K, Plesnila N, Augustinack J . Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci U S A. 2002; 99(23):15188-93. PMC: 137565. DOI: 10.1073/pnas.232473399. View

Manabat C, Han B, Wendland M, Derugin N, Fox C, Choi J . Reperfusion differentially induces caspase-3 activation in ischemic core and penumbra after stroke in immature brain. Stroke. 2003; 34(1):207-13. PMC: 2262098. DOI: 10.1161/01.str.0000047101.87575.3c. View

Sughrue M, Mocco J, Komotar R, Mehra A, DAmbrosio A, Grobelny B . An improved test of neurological dysfunction following transient focal cerebral ischemia in rats. J Neurosci Methods. 2006; 151(2):83-9. DOI: 10.1016/j.jneumeth.2005.04.023. View

OCollins V, Macleod M, Donnan G, Horky L, van der Worp B, Howells D . 1,026 experimental treatments in acute stroke. Ann Neurol. 2006; 59(3):467-77. DOI: 10.1002/ana.20741. View

Garcia L, Burda J, Hrehorovska M, Burda R, Martin M, Salinas M . Ischaemic preconditioning in the rat brain: effect on the activity of several initiation factors, Akt and extracellular signal-regulated protein kinase phosphorylation, and GRP78 and GADD34 expression. J Neurochem. 2003; 88(1):136-47. DOI: 10.1111/j.1471-4159.2004.02188.x. View

Koh S, Yoo A, Chang D, Hwang S, Kim S . Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions. Biochem Biophys Res Commun. 2008; 371(4):894-9. DOI: 10.1016/j.bbrc.2008.05.006. View

10.

Zhao H, Sapolsky R, Steinberg G . Phosphoinositide-3-kinase/akt survival signal pathways are implicated in neuronal survival after stroke. Mol Neurobiol. 2007; 34(3):249-70. DOI: 10.1385/MN:34:3:249. View

11.

Sena E, van der Worp H, Howells D, Macleod M . How can we improve the pre-clinical development of drugs for stroke?. Trends Neurosci. 2007; 30(9):433-9. DOI: 10.1016/j.tins.2007.06.009. View

12.

Jin R, Song Z, Yu S, Piazza A, Nanda A, Penninger J . Phosphatidylinositol-3-kinase gamma plays a central role in blood-brain barrier dysfunction in acute experimental stroke. Stroke. 2011; 42(7):2033-44. PMC: 3129812. DOI: 10.1161/STROKEAHA.110.601369. View

13.

Myers Jr M, Sun X, Cheatham B, Jachna B, Glasheen E, Backer J . IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. Endocrinology. 1993; 132(4):1421-30. DOI: 10.1210/endo.132.4.8384986. View

14.

Zhang L, Zhang Z, Liu X, Hozeska-Solgot A, Chopp M . The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat. Arterioscler Thromb Vasc Biol. 2007; 27(11):2470-5. DOI: 10.1161/ATVBAHA.107.150748. View

15.

Koh S, Chang D, Kim H, Kim J, Kim M, Kim K . Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology. 2005; 214(1-2):131-9. DOI: 10.1016/j.tox.2005.06.023. View

16.

Noshita N, Lewen A, Sugawara T, Chan P . Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2001; 21(12):1442-50. DOI: 10.1097/00004647-200112000-00009. View

17.

Bruning J, Winnay J, Cheatham B, Kahn C . Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol Cell Biol. 1997; 17(3):1513-21. PMC: 231877. DOI: 10.1128/MCB.17.3.1513. View

18.

Abe E, Fujiki M, Nagai Y, Shiqi K, Kubo T, Ishii K . The phosphatidylinositol-3 kinase/Akt pathway mediates geranylgeranylacetone-induced neuroprotection against cerebral infarction in rats. Brain Res. 2010; 1330:151-7. DOI: 10.1016/j.brainres.2010.02.074. View

19.

Rau T, Kothiwal A, Zhang L, Ulatowski S, Jacobson S, Brooks D . Low dose methamphetamine mediates neuroprotection through a PI3K-AKT pathway. Neuropharmacology. 2011; 61(4):677-86. DOI: 10.1016/j.neuropharm.2011.05.010. View

20.

Lee J, Kim K, Lee Y, Park S, Kim C, Lee W . Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther. 2003; 308(3):896-903. DOI: 10.1124/jpet.103.061853. View